Deutsche Post Jobs in Heidelberg und Umgebung

Deutsche Post und DHL

QuereinsteigerTarifvertragUnbefristetUrlaubsgeldVollzeitWeihnachtsgeld

2025-01-04

Jobbeschreibung

QuereinsteigerTarifvertragUnbefristetUrlaubsgeldVollzeitWeihnachtsgeld

Deutsche Post und DHL

Ketsch

2025-01-04

Jobbeschreibung

Beschreibung Werde Postbote für Briefe in Ketsch Was wir bieten – 17,60 € Tarif-Stundenlohn inkl. 50% Weihnachtsgeld und Regionalzulage – Weitere 50% Weihnachtsgeld im November – Bis zu 332 € Urlaubsgeld – Du kannst sofort in Vollzeit starten, 38,5 Stunden/Woche – Möglichkeit der Auszahlung von Überstunden und zusätzlichen Vergütung durch bspw. freiwillige Rufbereitschaft – Ein krisensicherer Arbeitsplatz, garantierte Gehaltssteigerung gemäß Tarifvertrag und pünktliche Gehaltszahlungen – Kostenlose Bereitstellung von hochwertiger Arbeitskleidung – Ausführliche Einweisung (bezahlt) – wir machen dich fit für die Zustellung – Unbefristete Übernahme und Entwicklungsmöglichkeiten (bspw. Standortleiter) bei guten Leistungen und offenen Positionen möglich – Attraktive Mitarbeiterangebote wie z.B. arbeitgeberfinanzierte betriebliche Altersvorsorge, Fahrradleasing, Rabatte bei Mobilfunkanbietern, etc. Deine Aufgaben als Postbote für Briefe – Zustellung von Briefsendungen mit zur Verfügung gestellten Hilfsmitteln – Auslieferung an 5 Werktagen (zwischen Montag und Samstag) – Übernehmen und Ordnen von Briefsendungen – Zustellung mit dem Fahrrad oder zu Fuß Was du als Zusteller bietest – Du kannst dich auf Deutsch unterhalten – Du fährst sicher Fahrrad im Straßenverkehr – Du bist wetterfest und kannst gut anpacken – Du bist zuverlässig und hängst dich rein Werde Postbote bei Deutsche Post DHL Als Briefzusteller machst du täglich die Menschen in deinem Bezirk glücklich und lässt dir von keinem Wetter die Laune verderben. Bei uns sind auch Quereinsteiger oder Studenten herzlich willkommen, denn du zählst, wie du bist! Wir freuen uns auf deine Bewerbung als Zusteller, am besten online! Klicke dazu einfach auf den ‚Bewerben‘-Button – auch ganz ohne Lebenslauf. MENSCHEN VERBINDEN, LEBEN VERBESSERN #werdeeinervonuns #werdeeinervonunspostbote #postbotefürbriefe #jobsNLMannheim

Postbote für Briefe (m/w/d)

QuereinsteigerTarifvertragUnbefristetUrlaubsgeldVollzeitWeihnachtsgeld

Deutsche Post und DHL

Ketsch

2025-01-04

Jobbeschreibung

2024-12-11

AppMaster

Jobbeschreibung

„Research for a life without cancer“ is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting. The German Cancer Research Center (DKFZ) is seeking a Postdoctoral Scientist for Artificial Intelligence in Oncology Reference number: 2024-0357 * Heidelberg * Full-time * Artificial Intelligence in Oncology To support the work on spatial genomics analyses of brain tumours, the Division of Artificial Intelligence in Oncology (headed by Prof. Dr. Moritz Gerstung) is seeking a postdoctoral scientist to join the team as soon as possible. These ongoing large-scale studies investigate the molecular mechanisms governing the microanatomical organisation across the spectrum of brain tumours [1]. The work is based on spatial transcriptomics, proteomics and genomics methods which provide a detailed molecular read out for millions of cells found in tumour tissues [2]. The lab develops and uses a range of data science and AI methods to distill biological knowledge from these large spatially resolved data sets and to extract biomarkers of disease progression [3,4]. This work is also closely related to efforts in digital pathology which provides the means to translate spatial genomics findings to a routine clinical setting [5,6]. References: [1] Z. Seferbekova, A. Lomakin, L. R. Yates, and M. Gerstung, “Spatial biology of cancer evolution,” Nat. Rev. Genet., vol. 24, no. 5, pp. 295–313, May 2023. [2] A. Lomakin et al., “Spatial genomics maps the structure, nature and evolution of cancer clones,” Nature, vol. 611, no. 7936, pp. 594–602, Nov. 2022. [3] L. Marconato et al., “SpatialData: an open and universal data framework for spatial omics,” Nat. Methods, Mar. 2024, doi: Website. Available: Website [4] V. Kleshchevnikov et al., “Cell2location maps fine-grained cell types in spatial transcriptomics,” Nat. Biotechnol., Jan. 2022, doi: Website. Available: Website [5] A. Shmatko, N. Ghaffari Laleh, M. Gerstung, and J. N. Kather, “Artificial intelligence in histopathology: enhancing cancer research and clinical oncology,” Nat Cancer, vol. 3, no. 9, pp. 1026–1038, Sep. 2022. [6] Y. Fu et al., “Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis,” Nat Cancer, vol. 1, no. 8, pp. 800–810, Aug. 2020. Your Tasks In this role, the candidate will engage in all relevant steps of the aforementioned research projects. This includes experimental design, development of statistical and AI methods, computational analyses of large data sets, manuscript writing and reproducible documentation. You will work in close collaboration with AI specialists, computational biologists, clinicians and experimentalists. Due to the sizeable complexity within these projects, the candidate is encouraged to help shape these projects, explore their own areas of interest, and contribute new ideas and approaches to our research efforts. Your Profile * Master's and PhD degree in life or physical sciences with focus on bioinformatics * Strong academic track record evidenced by peer-revied publications, preprints or other research outputs such as code repositories * Deep understanding of data science methodologies * Coding proficiency in Python, including PyTorch and other machine learning libraries * Knowledge of cancer biology * Affinity for collaborative work across discipline boundaries, international experience is an asset * Proficiency in spoken and written English We Offer * Excellent framework conditions: state-of-the-art equipment and opportunities for international networking at the highest level * Remuneration according to TV-L incl. occupational pension plan and capital-forming payments * 30 days of vacation per year * Flexible working hours * Possibility of part-time work * Family-friendly working environment * Sustainable travel to work: subsidized Germany job ticket * Our Corporate Health Management Program offers a holistic approach to your well-being * Develop your full potential: access to the DKFZ International Postdoc Program and DKFZ Career Service with targeted offers for your personal development to further develop your talents Contact: Eileen Haage Phone: +49 6221 42-4522 The position is initially limited to 2 years with the possibility of prolongation. Are you interested? Then become part of the DKFZ and join us in contributing to a life without cancer! Apply now We are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude. Notice: We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles. Share this job! Deutsches Krebsforschungszentrum | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de

Postdoctoral Scientist for Artificial Intelligence in Oncology

2024-12-11

AppMaster

Jobbeschreibung

2024-12-23

App

Jobbeschreibung

„Research for a life without cancer“ is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting. Bioinformatic Postdoc in Cancer Epigenomics Reference number: 2024-0374 * Heidelberg * Full-time * Cancer Epigenomics The Division of Cancer Epigenomics headed by Prof. Christoph Plass is offering an initial 2-year postdoc (extension possible) position for Cancer Epigenomics. Our division Website is a dynamic research team focused on understanding epigenetic contributions to carcinogenesis and therapy resistance in solid tumors (lung [1], breast [2], prostate [3]) and leukemia [4] with a focus on state-of-the-art wet lab technologies and computational solutions [5,6]. 1. Llamazares-Prada M, Schwartz U, Pease DF, Pohl ST, Ackesson D, Li R, Behrendt A, Tamas R, Richter M, Muley T, et al: Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration. bioRxiv 2023. 2. Zhang G, Jurinovic V, Bartels S, Christgen M, Christgen H, Kandt LD, Raap M, Klein J, Katzke A-L, Hofmann W, et al: Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences. medRxiv 2023. 3. Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, et al: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell 2018, 34:996-1011 e1018. 4. Weichenhan D, Riedel A, Sollier E, Toprak UH, Hey J, Breuer K, Wierzbinska JA, Touzart A, Lutsik P, Bahr M, et al: Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13). Blood Adv 2024, 8:5100-5111. 5. Scherer M, Singh I, Braun M, Szu-Tu C, Kardorff M, Rühle J, Frömel R, Beneyto-Calabuig S, Raffel S, Rodriguez-Fraticelli A, Velten L: Somatic epimutations enable single – cell lineage tracing in native hematopoiesis across the murine and human lifespan. bioRxiv 2024 6. Kelly K, Scherer M, Braun MM, Lutsik P, Plass C: EpiCHAOS: a metric to quantify epigenomic heterogeneity in single-cell data. Genome Biol 2024, 25:305. Your Tasks While the genetic components of therapy resistance have been extensively studied in various cancer types, non-genetic, including epigenetic, mechanisms of therapy resistance remain largely unexplored. Multiple mechanisms, including pre-existing persister cells or acquired resistance mediated by cell plasticity, will be tested in experimental model systems and patient-derived material using state-of-the-art single-cell epigenomic technologies. During this project, the candidate will use existing computational tools and develop new software solutions to understand epigenetic dysregulation leading to non-genetic therapy resistance. The candidate will investigate common mechanisms of cancer therapy resistance across the different cancer entities studied in the department, including solid tumors (lung, breast, prostate) or leukemia. Specifically, in close collaboration with technicians and wet-lab experts in the division, the candidate will analyze bulk (e.g., ACT-seq, ATAC-seq, WGS data, ONT long read sequencing) and single cell (scRNA-seq, scATAC-seq, scTAM-seq) data to understand epigenetic mechanisms of therapy resistance. Your Profile We are looking for a highly motivated bioinformatician or computational biologist with a PhD degree, interest in cancer research, and the ability to work in teams with molecular biologists. The candidate should have the following skills: * Good knowledge of R and/or Python * Previous experience in genomic data processing * Interest in interdisciplinary research * Knowledge of epigenomic data analysis is a plus * Fluency in English, German language skills are not required We Offer * Excellent framework conditions: state-of-the-art equipment and opportunities for international networking at the highest level * Remuneration according to TV-L incl. occupational pension plan and capital-forming payments * 30 days of vacation per year * Flexible working hours * Possibility of mobile work and part-time work * Family-friendly working environment * Sustainable travel to work: subsidized Germany job ticket * Our Corporate Health Management Program offers a holistic approach to your well-being * Develop your full potential: access to the DKFZ International Postdoc Program and DKFZ Career Service with targeted offers for your personal development to further develop your talents Contact: Michael Scherer Phone: +49 6221 42 3309 The position is initially limited to 2 years with the possibility of prolongation. Are you interested? Then become part of the DKFZ and join us in contributing to a life without cancer! Apply now We are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude. Notice: We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles. Share this job! Deutsches Krebsforschungszentrum | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de

Bioinformatic Postdoc in Cancer Epigenomics

2024-12-23

App

Jobbeschreibung

„Research for a life without cancer“ is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting. Bioinformatic Postdoc in Cancer Epigenomics Reference number: 2024-0374 * Heidelberg * Full-time * Cancer Epigenomics The Division of Cancer Epigenomics headed by Prof. Christoph Plass is offering an initial 2-year postdoc (extension possible) position for Cancer Epigenomics. Our division Website is a dynamic research team focused on understanding epigenetic contributions to carcinogenesis and therapy resistance in solid tumors (lung [1], breast [2], prostate [3]) and leukemia [4] with a focus on state-of-the-art wet lab technologies and computational solutions [5,6]. 1. Llamazares-Prada M, Schwartz U, Pease DF, Pohl ST, Ackesson D, Li R, Behrendt A, Tamas R, Richter M, Muley T, et al: Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration. bioRxiv 2023. 2. Zhang G, Jurinovic V, Bartels S, Christgen M, Christgen H, Kandt LD, Raap M, Klein J, Katzke A-L, Hofmann W, et al: Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences. medRxiv 2023. 3. Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, et al: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell 2018, 34:996-1011 e1018. 4. Weichenhan D, Riedel A, Sollier E, Toprak UH, Hey J, Breuer K, Wierzbinska JA, Touzart A, Lutsik P, Bahr M, et al: Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13). Blood Adv 2024, 8:5100-5111. 5. Scherer M, Singh I, Braun M, Szu-Tu C, Kardorff M, Rühle J, Frömel R, Beneyto-Calabuig S, Raffel S, Rodriguez-Fraticelli A, Velten L: Somatic epimutations enable single – cell lineage tracing in native hematopoiesis across the murine and human lifespan. bioRxiv 2024 6. Kelly K, Scherer M, Braun MM, Lutsik P, Plass C: EpiCHAOS: a metric to quantify epigenomic heterogeneity in single-cell data. Genome Biol 2024, 25:305. Your Tasks While the genetic components of therapy resistance have been extensively studied in various cancer types, non-genetic, including epigenetic, mechanisms of therapy resistance remain largely unexplored. Multiple mechanisms, including pre-existing persister cells or acquired resistance mediated by cell plasticity, will be tested in experimental model systems and patient-derived material using state-of-the-art single-cell epigenomic technologies. During this project, the candidate will use existing computational tools and develop new software solutions to understand epigenetic dysregulation leading to non-genetic therapy resistance. The candidate will investigate common mechanisms of cancer therapy resistance across the different cancer entities studied in the department, including solid tumors (lung, breast, prostate) or leukemia. Specifically, in close collaboration with technicians and wet-lab experts in the division, the candidate will analyze bulk (e.g., ACT-seq, ATAC-seq, WGS data, ONT long read sequencing) and single cell (scRNA-seq, scATAC-seq, scTAM-seq) data to understand epigenetic mechanisms of therapy resistance. Your Profile We are looking for a highly motivated bioinformatician or computational biologist with a PhD degree, interest in cancer research, and the ability to work in teams with molecular biologists. The candidate should have the following skills: * Good knowledge of R and/or Python * Previous experience in genomic data processing * Interest in interdisciplinary research * Knowledge of epigenomic data analysis is a plus * Fluency in English, German language skills are not required We Offer * Excellent framework conditions: state-of-the-art equipment and opportunities for international networking at the highest level * Remuneration according to TV-L incl. occupational pension plan and capital-forming payments * 30 days of vacation per year * Flexible working hours * Possibility of mobile work and part-time work * Family-friendly working environment * Sustainable travel to work: subsidized Germany job ticket * Our Corporate Health Management Program offers a holistic approach to your well-being * Develop your full potential: access to the DKFZ International Postdoc Program and DKFZ Career Service with targeted offers for your personal development to further develop your talents Contact: Michael Scherer Phone: +49 6221 42 3309 The position is initially limited to 2 years with the possibility of prolongation. Are you interested? Then become part of the DKFZ and join us in contributing to a life without cancer! Apply now We are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude. Notice: We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles. Share this job! Deutsches Krebsforschungszentrum | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de